| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 02/09/2005 | EP1503775A1 Formulations useful in the treatment of male and female impotence |
| 02/09/2005 | EP1503735A2 A direct cellular energy delivery system |
| 02/09/2005 | EP1503714A2 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 02/09/2005 | EP1503640A2 Make-up applicator with led light source |
| 02/09/2005 | EP1359925A4 A method to enhance the immune system and used for the prevention and treatment of asthma |
| 02/09/2005 | EP1284601A4 Allantoin-containing skin cream |
| 02/09/2005 | EP1282392B1 Oral composition |
| 02/09/2005 | EP1280535B1 Processes for preparing clarithromycin polymorphs |
| 02/09/2005 | EP1210119B1 Pharmaceutical compositions for oral and topical administration |
| 02/09/2005 | EP1098639B1 Use of the glucose uptake enhancer rosiglitazone for reducing ischaemia-induced apoptosis of pancreatic beta cells, endothelial cells and neuronal cells |
| 02/09/2005 | CN1578668A Salvianolic acid b |
| 02/09/2005 | CN1577272A Automatic detection and patching of vulnerable files |
| 02/09/2005 | CN1575816A Compounds for the treatment of female sexual dysfunction |
| 02/09/2005 | CN1188415C Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3', 5'-monophosphate phosphodiesterase (cGMP PDE5)for treatment of sexual dysfunction |
| 02/09/2005 | CN1188405C New Morpholinobenzamide salts |
| 02/09/2005 | CN1188141C Use of ginkgo biloba extracts for preparing a medicine |
| 02/09/2005 | CN1188128C Triazineone compounds for treating diseases due to sarcosystis neospora and toxoplasma |
| 02/09/2005 | CN1188106C Oral compsn. comprising 2'-hydroxypropiophenone |
| 02/08/2005 | US6852863 Osteoporosis; immunosuppressants; wound healing agent |
| 02/08/2005 | US6852858 Dissolving in solvents; precipitation; isolation; sleep disorders |
| 02/08/2005 | US6852729 Macrolides |
| 02/08/2005 | CA2151383C Stabilized medicinal aerosol solution formulation |
| 02/03/2005 | WO2005009398A2 Tetracyclic benzamide derivatives and methods of use thereof |
| 02/03/2005 | WO2005009397A2 Human lymphocyte vaccine adjuvant |
| 02/03/2005 | WO2005009396A2 Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections |
| 02/03/2005 | WO2005009395A2 Cellulosic fiber containing composition |
| 02/03/2005 | WO2005009394A2 Drug delivery in the nervous system |
| 02/03/2005 | WO2005009393A2 Stable radiopharmaceutical compositions and methods for preparation |
| 02/03/2005 | WO2005009392A2 Dihydropyrimidone inhibitors of calcium channel function |
| 02/03/2005 | WO2005009391A2 Antibiotic compound |
| 02/03/2005 | WO2005009390A2 Regulation of limbic system of the brain by neuro-coded signals |
| 02/03/2005 | WO2005009389A2 Anaplastic lymphoma kinase modulators and methods of use |
| 02/03/2005 | WO2005009388A2 Antiglucocorticoids for the treatment of catatonia |
| 02/03/2005 | WO2005009387A2 Azepine derivatives as pharmaceutical agents |
| 02/03/2005 | WO2005009386A2 Orally dissolving films |
| 02/03/2005 | WO2005009384A2 Egfr tyrosine kinase inhibitors |
| 02/03/2005 | WO2005009383A2 Methods of treatment with lxr agonists |
| 02/03/2005 | WO2005009382A2 Antiglucocorticoid therapy for the prevention of neurological damage in premature infants |
| 02/03/2005 | WO2005009381A2 Immediate-release formulation of acid-labile pharmaceutical compositions |
| 02/03/2005 | WO2005009380A2 Pharmaceutical formulations |
| 02/03/2005 | WO2005009379A2 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 02/03/2005 | WO2005009378A2 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 02/03/2005 | WO2005009377A2 Novel oral bioavailable prodrugs |
| 02/03/2005 | WO2005009376A2 Stable aluminum/zirconium antiperspirant solution |
| 02/03/2005 | WO2005009375A2 Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
| 02/03/2005 | WO2005009374A2 Ceramide dependent-stabilization of bace1 |
| 02/03/2005 | WO2005009373A2 Tyrosine kinase inhibitors |
| 02/03/2005 | WO2005009371A2 Ultra thin film transdermal/dermal or transmucosal/mucosal delivery system |
| 02/03/2005 | WO2005009370A2 Beta-carboline compounds and analogues thereof and their use as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
| 02/03/2005 | WO2005009369A2 A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
| 02/03/2005 | WO2005009367A2 Treatment of diseases with kinase inhibitors |
| 02/03/2005 | WO2005009366A2 Restoring vascular function |
| 02/03/2005 | WO2005009363A2 Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies |
| 02/03/2005 | WO2005009362A2 Muscarinic acetylcholine receptor antagonists |
| 02/03/2005 | WO2005009361A2 Method of treating hit patients with argatroban |
| 02/03/2005 | WO2005009360A2 Compositions related to a novel endophytic fungi and methods of use |
| 02/03/2005 | WO2005009359A2 Agents, compositions and methods for enhancing neurological function |
| 02/03/2005 | WO2005009358A2 Conformationally constrained parathyroid hormone (pth) analogs |
| 02/03/2005 | WO2005009357A2 Controlled release compositions |
| 02/03/2005 | WO2005009356A2 Method for the preparation of controlled release formulations |
| 02/03/2005 | WO2005009355A2 Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
| 02/03/2005 | WO2005009354A2 Compositions of a cyclooxygenase-2 selective inhibitor and an ikk inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury |
| 02/03/2005 | WO2005009351A2 Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabetics |
| 02/03/2005 | WO2005009350A2 Fugetactic proteins, compositions and methods of use |
| 02/03/2005 | WO2005009349A2 Composition and method for treating neurological disorders |
| 02/03/2005 | WO2005009348A2 Substituted purine derivatives |
| 02/03/2005 | WO2005009346A2 Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo |
| 02/03/2005 | WO2005009345A2 2-desmethyl ansamycin compounds |
| 02/03/2005 | WO2005009344A2 Acylated amino acid amidyl pyrazoles and related compounds |
| 02/03/2005 | WO2005009343A2 A1 adenosine receptor antogonists |
| 02/03/2005 | WO2005009340A2 Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith |
| 02/03/2005 | WO2005009339A2 Inflammatory bowel diseases |
| 02/03/2005 | WO2005009338A2 Method of inhibiting atf/creb and cancer cell growth and pharmaceutical compositions for same |
| 02/03/2005 | WO2005009337A2 Treating severe acute respiratory syndrome |
| 02/03/2005 | WO2005009335A2 Live attenuated nidovirus vaccines |
| 02/03/2005 | WO2005009333A2 Combined treatments comprising synthetic peptide copolymers for preventing graft rejection |
| 02/03/2005 | WO2005009332A2 Compositions-of-matter for lowering serum cholesterol and/or triglyceride level and methods of producing and using same |
| 02/03/2005 | WO2005009330A2 Method of obtaining inhibitors of type ii dehydroquinase enzyme and precursors thereof |
| 02/03/2005 | WO2005009217A2 Diagnosis of pre-cancerous conditions using pcdgf agents |
| 02/03/2005 | WO2004100863A3 Composition for preventing and treatment of asthma comprising alpha-lipoic acid as an effective component |
| 02/03/2005 | WO2004098522A3 Gemini vitamin d3 compounds and methods of use thereof |
| 02/03/2005 | WO2004091516A3 Methods for controlling the proliferation of cells |
| 02/03/2005 | WO2004087101A3 Oral formulations of cladribine |
| 02/03/2005 | WO2004080399B1 Rapidly absorbing lipophilic skin compositions and uses therefor |
| 02/03/2005 | WO2004078122A3 Invisible patch for active agnet controlled delivery |
| 02/03/2005 | WO2004075840A3 Selective non-steroidal glucocorticoid receptor modulators |
| 02/03/2005 | WO2004071425A3 The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions |
| 02/03/2005 | WO2004064755A3 Methods for inhibiting proteasome |
| 02/03/2005 | WO2004052299B1 Modification of cyclooxygenase and lipoxygenase activity with asteridae extracts and optionally boswellic acid |
| 02/03/2005 | WO2004052277A3 Anthrax antitoxins |
| 02/03/2005 | WO2004041196A3 Methods and compositions for the diagnosis of neuroendocrine lung cancer |
| 02/03/2005 | WO2004024089A3 Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing |
| 02/03/2005 | WO2003096988A3 Tr4/tr2 response elements |
| 02/03/2005 | US20050027184 Apparatus and method to measure platelet contractility |
| 02/03/2005 | US20050027156 Intraocular brachytherapy device and method |
| 02/03/2005 | US20050027129 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| 02/03/2005 | US20050027110 Nontoxic lectin conjugated to therapeutic agent for use in treatment and prevention of nervous system disorders |
| 02/03/2005 | US20050026922 For treating CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression; side effect reduction; for example, (7R,9aS)-trans-7-[6-(2,6-Dimethyl-piperidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine |
| 02/03/2005 | US20050026919 Administering to subject a cyclooxygenase-2 selective inhibitor or an isomer, salt, ester, or prodrug thereof in combination with a cholinergic agent or an isomer, salt, ester, or prodrug thereof; combination therapy for treating a stroke |
| 02/03/2005 | US20050026894 2-Desmethyl ansamycin compounds |